ALB and neoplasm: PERTINENT FINDINGS: Albumin binder–conjugated FAPI radiopharmaceuticals exhibited notably improved tumor uptake and retention compared with the original FAPI tracers and showed remarkable inhibition of PDX tumor growth, with negligible side effects.